Skip to NavigationSkip to content

Moderna commits 100 million COVID-19 vaccine doses to the US

Published on 12/08/20 at 10:07am

Moderna continues to rise to meet the demands of the pandemic, signing a new deal with the US Government to supply 100 million doses of its messenger RNA (mRNA) vaccine candidate for the prevention of COVID-19.

The agreement commits up to $1.525 billion to cover the manufacture and delivery of candidate mRNA-1273, and includes “incentive payments” to encourage that the vaccine is delivered as quickly as possible.

This follows the previous agreement of up to $955 million signed by Moderna with the Biomedical Advanced Research and Development Authority (BARDA), meaning the US Government has now committed $2.48 billion in total to the research and delivery of the vaccine candidate under its Operation Warp Speed.

“For Operation Warp Speed, we are assembling a broad portfolio of vaccines to increase the odds that we will have at least one safe, effective vaccine as soon as the end of this year,” commented Alex Azar, US Secretary of Health and Human Services. “With this latest investment, we will have supported the vaccine candidate developed by Moderna in partnership with the NIH all the way from early development through clinical trials and now manufacturing, with the potential to bring millions of safe and effective doses to the American people.”

Under the terms of the deal, the US Government will also have the option to reserve a further 400 million doses of the vaccine.

“We appreciate the confidence of the US Government in our mRNA vaccine platform and the continued support,” remarked Stéphane Bancel, Moderna’s Chief Executive Officer. “We are advancing the clinical development of mRNA-1273 with the ongoing Phase 3 study being conducted in collaboration with NIAID and BARDA. In parallel, we are scaling up our manufacturing capability with our strategic partners, Lonza, Catalent and Rovi, to address this global health emergency with a safe and effective vaccine.”

Matt Fellows

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches